Trial reportBritish journal of clinical pharmacology2006
Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.
Trial report in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03691961 (Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children.The Cochrane database of systematic reviews · 2006Pooled it
- A Pilot Study of the Normative Range of Overnight Urinary Free Cortisol Corrected for Creatinine in Children.Clinical drug investigation · 2018Trial
- Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy.British journal of clinical pharmacology · 2013Trial
- Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.The European respiratory journal · 2012Trial
- In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler.British journal of clinical pharmacology · 2009Trial
- Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler.British journal of clinical pharmacology · 2008Trial
- Sustained control of recalcitrant chronic spontaneous urticaria after initiation of inflammatory airway diseases treatment: two case reports.Journal of medical case reports · 2024Article
- Article
- Nebulized dexamethasone sodium phosphate in the treatment of horses with severe asthma.Journal of veterinary internal medicine · 2021Article
- Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).Journal of aerosol medicine and pulmonary drug delivery · 2014Article
- Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.ACS medicinal chemistry letters · 2014Article
- A pharmacokinetic simulation tool for inhaled corticosteroids.The AAPS journal · 2013Article
- Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.British journal of clinical pharmacology · 2007Article
- From pharmacology to immunopharmacology.British journal of clinical pharmacology · 2006Article
- Severe asthma in children.The journal of allergy and clinical immunology. In practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo compare the pharmacokinetic profiles of beclometasone, budesonide, fluticasone and mometasone following inhalation in patients with asthma, and explore the relationship between lung function and plasma drug concentrations.
methodsThirty subjects with asthma and a forced expiratory volume in 1 s (FEV(1)) ranging from 36 to 138% predicted, inhaled 800 microg beclometasone, budesonide and mometasone and 1000 microg fluticasone in random order. Plasma drug concentrations were measured over 8 h and the relationship between the area under the plasma concentration-time curve (AUC(0-8)) and lung function was modelled using linear regression. Estimated AUC(0-8) values at 50 and 100% predicted FEV(1) were compared for each drug.
resultsPharmacokinetic profiles differed markedly between the drugs. Correlation coefficients for the relation between FEV(1)% predicted and AUC(0-8) values for beclometasone, budesonide, fluticasone and mometasone were 0.37 (P = 0.05), 0.33 (P = 0.08), 0.25 (P = 0.2) and 0.52 (P = 0.004), respectively, and estimated AUC(0-8) values were 1.3 [95% confidence interval (CI) 1.0, 1.8], 1.3 (95% CI 1.0, 1.8), 1.4 (95% CI 0.9, 2.2) and 2.2 (95% CI 1.3, 3.5) times higher for the four drugs, respectively, at 100 compared with 50% predicted FEV(1.)
conclusionThe higher plasma concentrations of inhaled corticosteroids in patients with a higher FEV(1)% predicted suggests that, for any given dose, these patients will be at greater risk of developing adverse systemic effects with long-term use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.